Enhancing TCR-T cell responses with a TGFbeta-specific chimeric antigen receptor

Authors: Weist, Michael R; BenDavid, Ethan; Munguia, Melanie L; Reyes, Jessica; Chen, Ximin; Parisi, Giulia; Cui, Jiajia; Foord, Orit; Chen, Yvonne Y; Johnston, James A

Source journal: Neoplasia (New York, N.Y.) (2026-11-10)

DOI: 10.1016/j.neo.2026.101398

Abstract

BACKGROUND: Overcoming the suppressive tumor microenvironment (TME) remains an important unmet challenge for chimeric antigen receptor (CAR)-T cell therapies. Transforming growth factor beta (TGFbeta) is a key driver of T-cell suppression, reducing T-cell receptor (TCR)-mediated cytotoxicity and driving the differentiation of immunosuppressive regulatory T cells (Tregs) in the TME. METHODS: To overcome TGFbeta-mediated immunosuppression, we employed a TGFbeta-targeting CAR coexpressed with a human papillomavirus type 16 (HPV16) E7(11-19)-specific, HLA-A*02:01-restricted TCR (E7 TCR) in T cells. TGFbeta-CAR constructs incorporating either CD28 or 4-1BB costimulatory domains were evaluated for their effects on T-cell function and phenotype. RESULTS: Compared with T cells expressing E7 TCR only or E7 TCR with an irrelevant CD19 CAR, T cells co-transduced with E7 TCR and TGFbeta-CAR showed enhanced proliferation and cytokine production while maintaining cytotoxicity upon repeated rounds of challenge with HPV16(+) Ca Ski tumor cells, which provided a natural source of active TGFbeta in coculture. TGFbeta-CAR-expressing T cells also exhibited reduced exhaustion-marker expression and Treg differentiation after repeated antigen challenges. Transcriptional analysis further showed reduced FOXP3 expression and enhanced expression of proinflammatory genes including IFNG. In mice bearing B16-F10 tumors, TGFbeta-BB-zeta-expressing pmel-1 cells reduced tumor burden and prolonged progression-free survival versus PBS and increased circulating donor T cells versus mock-transduced controls. CONCLUSIONS: Together, these data demonstrate that TGFbeta-CAR can enhance T-cell effector function while limiting Treg differentiation, supporting its development as a platform to improve the function and persistence of TCR-T cell therapies in suppressive TMEs.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.